What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

ATE Insider Trading (Antibe Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$50,722.00
Insider Selling (Last 12 Months): C$300,300.00

Antibe Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Antibe Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Antibe Therapeutics Share Price & Price History

Current Price: C$0.89
Price Change: Price Decrease of -0.04 (-4.30%)
As of 10/19/2021 01:00 AM ET

This chart shows the closing price history over time for ATE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"

Antibe Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2021Daniel Marcel LegaultDirectorBuy12,500C$1.02C$12,750.00776,296
7/14/2021Scott Wilson CurtisSenior OfficerBuy2,600C$3.42C$8,892.0037,000
7/13/2021Daniel Marcel LegaultDirectorBuy4,000C$3.57C$14,280.00763,796
6/30/2021Daniel Marcel LegaultDirectorBuy4,000C$3.70C$14,800.00759,796
6/3/2021Daniel Marcel LegaultDirectorSell75,000C$4.00C$300,300.00755,796
9/24/2020Daniel Marcel LegaultDirectorBuy75,000C$0.34C$25,500.00375,000
9/24/2020David James VaughanSenior OfficerBuy52,500C$0.34C$17,850.0052,500
9/22/2020John Lawrence WallaceDirectorBuy71,500C$0.37C$26,455.00348,270
9/21/2020Scott Wilson CurtisSenior OfficerBuy30,000C$0.35C$10,500.00309,000
6/3/2020Daniel Marcel LegaultDirectorSell259,500C$0.61C$156,997.50525,000
6/3/2020Scott Wilson CurtisSenior OfficerSell24,000C$0.61C$14,640.00246,000
6/1/2020Daniel Marcel LegaultDirectorSell1,250,000C$0.61C$762,500.00800,000
6/1/2020David James VaughanSenior OfficerSell150,000C$0.60C$90,000.0055,000
10/24/2019Roderick John FlowerDirectorSell120,000C$0.45C$53,400.00212,492
5/13/2019Daniel Marcel LegaultDirectorBuy35,000C$0.34C$11,900.00265,000
11/27/2018Daniel Marcel LegaultDirectorBuy50,000C$0.25C$12,500.00
See Full Table
Insider Trading at Antibe Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Antibe Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Antibe Therapeutics (TSE:ATE)

Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More on Antibe Therapeutics

Today's Range

Now: C$0.89
Low: C$0.85
High: C$0.94

50 Day Range

MA: C$1.22
Low: C$0.93
High: C$1.51

52 Week Range

Now: C$0.89
Low: C$0.85
High: C$7.52

Volume

724,806 shs

Average Volume

224,369 shs

Market Capitalization

C$45.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Antibe Therapeutics?

Antibe Therapeutics' top insider investors include:
  1. Daniel Marcel Legault (Director)
  2. John Lawrence Wallace (Director)
  3. Scott Wilson Curtis (Senior Officer)
  4. Roderick John Flower (Director)
  5. David James Vaughan (Senior Officer)
What The White House Is NOT Telling You About The "Green Revolution."
Governments across the globe want to go "All Electric" by 2035. There's one rare metal that could cripple these plans. Without it, going green is impossible. And that's why there's a modern-day gold-rush for this rare metal.
Read The Full Story On This "Gold Rush"